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ABSTRACT
We report a case of a 65-year-old female patient
treatedwith an everolimus-eluting bioresorbable
scaffold (BRS) after rotational atherectomy of a
severely calcified lesion of the left anterior
descending coronary artery. The implanted BRS
restenosed 10 months after implantation and
was treated with a scoring balloon followed by
drug-eluting balloons with good immediate and
long-term results. To the best of our knowledge,
this is the first report of a balloon-only treatment
of a restenosis occurring more than 6 months
after BRS implantation; angiographic and optical
coherence tomography images after treatment
and at two-year follow-up are presented.
Keywords: Bioresorbable vascular scaffold;
Calcified coronary lesions; Drug eluting
balloon; Rotational atherectomy; Scoring
balloon
CASE REPORT
A 65-year-old female patient presented in January
2013 with unstable angina. Coronary
angiography showed a severely calcified long
lesion of the proximal and mid segments of the
left anterior descending coronary artery [Video S1
(please see enhanced content link on title page)].
In view of the angiographic findings, a decision
was taken to do a planned rotational atherectomy
(RA), whichwas performedwith the RotablatorTM
(Boston Scientific) using 1.5 then 1.75 mm burr
sizes, followed by implantation of two
overlapping 3.0 9 28mm bioresorbable scaffolds
(BRS) (AbsorbTM, Abbott). Post-dilatation was
done using a 3.0 mm non-compliant balloon at
20 atm. Intravascular ultrasound (IVUS) showeda
good result with a minimal overlapping zone
(Fig. 1). A coronary angiography done 10 months
later due to recurrent angina revealed a significant
restenosis of the implanted BRS. Optical
coherence tomography (OCT) showed a diffuse
homogeneous intra-scaffold neointimal tissue
with a minimum luminal area of 1.59 mm2 at
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the distal BRS and 1.98 mm2 at the proximal one
(Fig. 2). A scoring balloon angioplasty using a
3.0 9 10mm AngioSculptTM scoring balloon
(AngioScore) was performed followed by
3.5 9 20 and 3.0 9 20 mm Pantera LuxTM
(Biotronik) paclitaxel eluting balloons (DEB) in
the proximal and distal scaffolds, respectively.
OCT clearly showed the neointimal cuts achieved
by the scoring elements (white arrowheads,
Fig. 3), neointimal disruption with some
intraluminal material (yellow arrowheads, Fig. 3)
and lumen expansion. At 2 years after balloon
angioplasty (almost 3 years after BRS
implantation), the patient remained
asymptomatic and a scheduled angiographic
control showed a patent vessel with no
significant lesions. OCT showed favorable
evolution of the neointimal damage caused by
the scoringballoonandmaintenanceof the initial
lumen expansion, with partial resorption of the
scaffold struts for which footprints were still
visible (Fig. 4).
Fig. 1 Baseline angiogram and procedure. A Baseline
angiogram showing a calciﬁed stenosis of the proximal
and mid LAD. B Lesion preparation with rotational
atherecomy using the 1.75 burr. C Shows ﬁnal result after
implantation of two 3 9 28 mm bioresorbable scaffolds,
with a good result in the ﬁnal intravascular ultrasound (D)
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Compliance with Ethics Guidelines
Informed consent was obtained from the
patient for being included in the study.
DISCUSSION
The most important proposed advantage of BRS
over the current metallic stent technology is to
restore the natural physiologic vasomotor
function and to hinder late thrombotic events.
In our case, the initial treatment strategy was
using RA in disrupting the continuity of
intravascular calcium rings facilitating BRS
implantation and potentially achieving a
stent-free vessel in the long-term.
RA is a safe and effective method for lesion
preparation before stent implantation [1] and
its use could be extrapolated before BRS
implantation, where lesion preparation is of
utmost importance. However, additional vessel
injury with RA has been previously suggested to
be associated with increased late lumen loss [2].
In our case, this mechanism appears very likely
because the in-scaffold restenosis was diffuse
and affected both implanted BRSs.
The rate of target-lesion revascularization
ranges from 1 % to 3.3 % after BRS
Fig. 2 In-scaffold restenosis. In A, B, the angiogram shows
diffuse in-scaffold restenosis in the proximal and distal
scaffolds. B is the ﬁnal angiographic appearance after
scoring balloon/drug-eluting balloon treatment. Optical
coherence tomography (OCT) images (a) and (c) show
homogeneous intra-scaffold tissue. The b represents OCT
cross section of the overlapping zone
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implantation [3, 4]. The most often used method
for the treatment of in-scaffold restenosis is a
drug-eluting stent (DES) [5], but there is no
sufficient data supporting this approach, and the
optimal treatment strategy is still uncertain.
Drug-eluting balloons have demonstrated their
efficacy in treatment of restenosis following
metallic stent implantation [6]. Additionally,
scoring balloon predilatation prevents balloon
slippage and enhances local plaque disruption,
and its use in combination with DEB angioplasty
improved angiographic results in the
ISAR-DESIRE 4 Study [7]. In this reported case,
by adopting the scoring/paclitaxel-coated
balloon strategy, we tried avoiding a metallic
stent implantation targeting to maintain the
long-term benefits of BRS. The entire resorption
process of BRS takes approximately 3 years to
complete. However, between 3 and 6 months
and as a consequence of hydrolysis of ester
bonds, the device loses its structural continuity,
and the radial strength decreases considerably
until it is lost [8]. This loss of radial force is
suspected to be source of recoil when balloon
dilatation is performed alone after 6 months. In
this patient, the vessel wall 10 months after BRS
implantation opposed minimal recoil to the
scoring/DEB treatment, which achieved
sufficient stable lumen size and remained
effective until 2 years of follow-up.
Fig. 3 Final result after scoring balloon/drug-eluting
balloon treatment. In A, B, the ﬁnal angiographic
appearance after balloon-only treatment of the restenosis.
d–f Lumen expansion is clearly visible via optical coherence
tomography (OCT). The white arrowheads show the
lumen-surface marks achieved by the scoring elements.
Intraluminal material caused by neointimal dissection is
also observed (yellow arrowhead)
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In our case we tried to highlight the possibility
of a balloon-only treatment of a restenosed
bioresorbable scaffold. With an adequate initial
lesion preparation, this strategy can be even
applied in severely calcified coronary lesions.
Finally, given the limited data, there is a need for
further examination of the place of RA before BRS
implantation and the optimal treatment strategy
for in-scaffold restenosis from future RCTs.
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